Olink to present at the 40th Annual J.P. Morgan Healthcare Conference
Olink Holding AB (Nasdaq: OLK) will participate in the 40th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Olink Holding AB (Nasdaq: OLK) will participate in the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 9:00 am ET. CEO Jon Heimer is scheduled to present, with a live and archived webcast available on the company’s website. Olink focuses on accelerating proteomics to enable new scientific discoveries and improve patient outcomes. Founded in 2016, Olink is established in Europe, North America, and Asia, providing products and services for biopharmaceutical companies and academic institutions.
Details
News Market Reaction – OLK
The recorded move for OLK in the trading session of this news was -11.06%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UPPSALA, Sweden, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK), today announced it will be virtually participating in the 40th Annual J.P. Morgan Healthcare Conference.
Jon Heimer, CEO, is scheduled to present on Wednesday, January 12th, 2022, at 9:00 am ET.
A live and archived webcast of the event will be available on the “Investors” section of the Company’s website at https://investors.olink.com/investor-relations.
About Olink
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.
For more information please contact:
IR Contact
Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
jan.medina@olink.com
Media Contact
Andrea Prander
Corporate Communications Manager
Mobile: + 46 768 775 275
andrea.prander@olink.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.